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Background
Attention-deficit hyperactivity disorder (ADHD) is common
among people with intellectual disability. Diagnosing ADHD in
this clinically and cognitively complex and diverse group is
difficult, given the overlapping psychiatric and behavioural
presentations. Underdiagnoses and misdiagnoses leading to
irrational polypharmacy and worse health and social outcomes
are common. Diagnostic interviews exist, but are cumbersome
and not in regular clinical use.
Aims
We aimed to develop a screening tool to help identify people with
intellectual disability and ADHD.
Method
A prospective cross-sectional study, using STROBE guidance,
invited all carers of people with intellectual disability aged 18–50
years open to the review of the psychiatric team in a single UK
intellectual disability service (catchment population: 150 000). A
ten-item questionnaire based on the DSM-V ADHD criteria was
circulated. All respondents’ baseline clinical characteristics were
recorded, and the DIVA-5-ID was administered blinded to the
individual questionnaire result. Fisher exact and multiple logistic
regressions were conducted to identify relevant questionnaire
items and the combinations that afforded best sensitivity and
specificity for predicting ADHD.
Results
Of 78 people invited, 39 responded (26 men, 13 women), of whom
30 had moderate-to-profound intellectual disability and 38 had
associated comorbidities and onweremedication, including 22 on
psychotropics. Thirty-six screened positive for ADHD, and 24were
diagnosed (16 men, eight women). Analysis showed two positive
responses on three specific questions to have 88% sensitivity and
87% specificity, and be the best predictor of ADHD.
Conclusions
The three-question screening is an important development for
identifying ADHD in people with intellectual disability. It needs
larger-scale replication to generate generalisable results.
Keywords
Attention-deficit hyperactivity disorders; comorbidity; develop-
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Attention-deficit hyperactivity disorder (ADHD) is a neurodeve-
lopmental disorder characterised by a persistent pattern of inatten-
tion and/or hyperactivity and impulsivity, with an onset in
childhood, and causes significant functional impairment to the indi-
vidual.1 The prevalence rate is 5.9% in youth and 2.5% in adults.2 It
is estimated to be much higher among people with intellectual dis-
ability.3 Some studies have estimated a prevalence of around 20%.4
ADHD causes significant functional impairment in physical, mental
and social well-being.2,5 Treatment of ADHD has shown to improve
long-term outcomes such as obesity, non-medicinal drug use/
addictive behaviour, antisocial behaviour, use of health services,
self-esteem and social function outcomes.2,6
Although there is a higher prevalence of ADHD in people with
intellectual disability, ADHD continues to remain underdiagnosed
and misdiagnosed in this population.7,8 Various reasons can be
hypothesised as contributory factors for this underdiagnosis (Table
1). Diagnostic overshadowing particularly of misdiagnosing ‘challen-
ging behaviour’ can also be amanifestation of underlying unrecognised
ADHD in people with intellectual disability.9 Effective treatment of
ADHD has a positive effect on symptom control and reduction of the
core features of ADHD, as well as quality of life and daily function-
ing.9,10,11 People with intellectual disability and ADHD are less likely
to use antipsychotic medications compared with their peers who are
not receiving ADHD treatment.9,10,12 Hence, it is imperative that
ADHD is identified as early as possible, and managed appropriately.
The Diagnostic Interview for ADHD in adults with intellectual
disability (DIVA-5-ID) is a diagnostic tool recommended for use in
people with intellectual disability.13 Using the DIVA-5-ID requires
significant resources and time. For the general population, validated
screening tools can be used before using the DIVA-5.14 However,
for people with intellectual disability, there is no such validated
screening tool. The screening tools that are currently available
from general population are of limited use in people with intellec-
tual disability.12 They were developed in general population,
making their routine application in people with intellectual disabil-
ity problematic without further testing. In addition, the predictive
validity of these tools is invariably poorer when used outside of
the sample in which they were developed. Further, there is no
consensus on which outcomes are the most important.15 This
paper seeks to provide an evidence-based concept for a screening
tool specific for people with intellectual disability and ADHD.
Aim
We aimed to identify the predictive ability of specific symptoms of
ADHD as applied to people with intellectual disability, to develop a
screening tool.
Method
Study design and development sample
This is a cross-sectional study undertaken in January 2019, using
the Strengthening the Reporting of Observational Studies in
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Epidemiology (STROBE) guidance. The study population was
people with intellectual disability aged 18–50 years, open
to review of the psychiatric team of a specialist National Health
Service (NHS) intellectual disability service in the UK, covering a
catchment of 152 000 people. Those aged >50 years or with a diag-
nosis of dementia were not included.
The service was developing pathways for various neurodevelop-
mental conditions and was using screening tools developed by
clinicians as part of routine practice. For ADHD, a ten-item ques-
tionnaire was developed based on the current DSM-V ADHD diag-
nostic criteria, with an additional question relating to challenging
behaviour (Appendix 1).16
The ten items were chosen based on a previous study highlight-
ing that certain items used in the process of diagnosing ADHD in
general population (i.e. ‘loosing things’, ‘forgetful in daily activities’,
‘talking excessively’, ‘often blurt out answers’ and ‘interrupt or
intrude on others’) were not reliable in people with intellectual dis-
ability.17 The items that were left out relied on the patient possessing
a higher level of functioning.
The recruitment process is provided in Appendix 2. The ques-
tionnaire was sent to the carers of people with intellectual disability,
with instructions to be completed by a person who knew the patient
well. The service clinicians assessed all of the patients whose carers
replied to the questionnaire, using the DIVA- 5-ID, before reviewing
the questionnaire. If one ormore questions on the questionnaire were
answered ‘yes’, it was considered a positive screening. Comparisons
were then made between DIVA-5-ID and the questionnaire results.
Baseline patient characteristics of all respondents, including gender,
age, level of intellectual disability, number and type of comorbidities,
and prescribed psychotropic medication was collected.
Ethics/governance
The project was done with anonymised data from a single centre. No
patient data was shared outside of the clinical team. Data were col-
lected as part of ongoing service evaluation, formally registered
with the host NHS organisation. The NHS Health Research
Authority tool (http://www.hra-decisiontools.org.uk/research/index.
html) was used to confirm that no ethics approval was needed for
this project (Supplementary File 1 available at https://doi.org/10.
1192/bjo.2021.1023). No author had access to any patient-identifiable
information other than that of their own clients in their service. All
survey recipients had been informed of the reasons for the survey,
that consent was given via return of the survey, that data would be
used for both clinical and research use and all data would be anon-
ymised before sharing outside of the clinical team.
Statistical analysis
A specialist statistician outlined a four-stage approach to identify
the reliability of the questionnaire questions compared with the
gold-standard DIVA-5-ID.
Stage 1
The separate association between each of the ten screening ques-
tions and the DIVA-5-ID results across all participants was exam-
ined with Fisher’s exact test.
Stage 2
The DIVA-5-ID result was used as the outcome variable, with the
screening questions as the predictor variables, using multiple logistic
regression. To simplify the regression model, variables not found to
be associated with the outcome were omitted from the model. This
was done with a backward-selection approach, with the question
with the largest P-value removed at each point. It was recognised
that because of the relatively small sample size, questions could be
associated with the DIVA-5-ID result, but not achieve statistical sig-
nificance. Therefore, two different approaches were considered,
resulting in two different models. The first model (model 1) included
all variables where the odds ratio was >2. A second approach (model
2) only included questions in the final model if the P-value was <0.2.
For each variable in the two models, results are presented as odds
ratios for each question, with their corresponding confidence inter-
vals. These give the odds of a positive DIVA-5-ID result when the
answer was ‘yes’ compared with odds when the answer was ‘no’.
Stage 3
The next stage aimed to determine a score based on the screening
questions that could best be used to predict the DIVA-5-ID result.
The regression coefficients for each question were calculated. A
rule was established that for any question found to be significant,
they would be multiplied by their effect size based on their individ-
ual regression coefficients.
(a) Score 1: All questionnaire questions with >20% difference in
positive DIVA-5-ID rates between responses, regardless of
statistical significance.
(b) Score 2: Questionnaire questions with an odds ratio of >2 from
the multiple logistic regression analysis, regardless of statistical
significance.
(c) Score 3: Questionnaire questions with a P-value of <0.2 from
the multiple logistic model.
(d) Score 4: As score 3, but giving more weight to questions more
associated with the DIVA-5-ID result.
Stage 4
The final analyses examined the ability of the collective scores (1–4)
to predict the DIVA-5-ID result. Receiver operating characteristic
(ROC) curves were used to examine the predictive ability, with
the area under the ROC curve quantifying the performance. The
ROC curves were used to choose an optimal cut-off point for each
score that could best predict the DIVA-5-ID result. The cut-off
point was chosen so as to give the best combination of sensitivity
and specificity. The positive and negative predictive values and diag-
nostic odds ratio have also been showcased.
Table 1 Complexity contributing to underdiagnoses and misdiagnosis
of ADHD in people with intellectual disability
Challenges in diagnosing ADHD in intellectual disability
1. Patient factors
• Communication difficulties limit the person’s ability explain ADHD
symptoms
• High neurodevelopmental comorbidities, such as autism spectrum
disorder, affecting/masking symptoms of ADHD
• High prevalence rate of mental illness affecting/masking symptoms
of ADHD
• Effect of ADHD symptoms may be limited because of the person’s
level of intellectual disability
• Difficulty defining whether inattention and hyperactivity symptoms
are attributable to intellectual disability or ADHD
• ADHD may be manifested as challenging behaviour
2. Clinical factors
• Difficulties obtaining a developmental history
• Difficulties in defining functional impairment
• Several DSM-V ADHD criteria are not applicable for people with
intellectual disability and communication difficulties
• Limited published research in ADHD in intellectual disability
• Lack of awareness and training in diagnosis and treatment of ADHD
in intellectual disability
• Ambivalence about the existence of ADHD in intellectual disability
ADHD, attention-deficit hyperactivity disorder.
Sawhney et al
2
Downloaded from https://www.cambridge.org/core. 04 Oct 2021 at 12:50:37, subject to the Cambridge Core terms of use.
Results
The recruitment numbers by stage are outlined in Appendix 2. There
were 78 eligible people open to the psychiatric team. Of the 78 ques-
tionnaires sent out, 39 (50%) were returned; 26 male (66%) and 13
female (33%) respondents, with a mean age of 38 years. Thirty had
moderate-to-profound intellectual disability (77%) and nine had
mild intellectual disability (33%). Only one person did not have a
comorbid health issue. Of the 38 respondents with comorbid health
issues, 14 had one (36%), 14 had two (36%) and ten had three or
more (26%) comorbid conditions. Specific psychiatric comorbidities
and the number of patients with the diagnosis are provided in Table 2.
Just one person was not on any medication. Seven people were
on one medication, 15 were on two medications and 16 were on
three or more medications. Looking specifically at psychotropics,
22 people were prescribed antipsychotics (56%), 17 were prescribed
antidepressants (44%), 12 were prescribed anti-seizure medication
(31%) and 10 were prescribed mood stabilisers (26%); 21 people
were prescribed two or more psychotropics (54%). The specific
drugs and number of patients prescribed are provided in Table 2.
Of the 39 respondents, 36 (92%) had answered at least one ques-
tion of the questionnaire positively, with three replying negatively to
all questions. The corresponding DIVA-5-ID of all 39 respondents
was completed, which identified 24 (61%) as having ADHD, of
whom 16 were male (67%) and eight were female (33%).
Stage 1
Significant associations (P < 0.05) with the DIVA-5-ID were found
for questions 1, 2, 3 and 6, and borderline significance (P = 0.06) for
question 8 (Table 3). For the questions where a significance was
seen, DIVA-5-ID responses of ‘yes’ were in, higher numbers for
questions 1 and 2 where >90% answered ‘yes’ compared with less
than 40% answering ‘no’.
Stage 2
The logistic regression of model 1, comprising five questions (odds
ratio > 2; i.e. questions 1, 2, 3, 6 and 7), had a greater than two times
odds of a positive DIVA-5-ID result with a ‘yes’ compared with a
‘no’ response (Table 4). Only question 2 was statistically significant
(P < 0.05). As per the statistical plan, variables with larger P-values
(≥ 0.2) were removed from model 1, leaving three questions for
model 2 (i.e. questions 1, 2 and 6). Question 2 was the most associated
with DIVA-5-ID result, with borderline significance (P = 0.05). For
question 2, the odds ratiowas 16 times higher for a positiveDIVA-5-ID
result and a ‘yes’ response compared with a ‘no’ response.
Stage 3
Each eligible question in the scores 1–4 was allotted one point for a
‘yes’ response and no points for a ‘no’ response. The exception was
for score 4, where a ‘yes’ response to question 2 was allotted 2 points,
as this variable was found to be most associated with a positive
DIVA-5-ID score, as the regression coefficient for question 2 was
approximately twice that of questions 1 and 6, which were
similar. The scores were as follows, where Q indicates question:
(a) Score 1: Q1 + Q2 + Q3 + Q5 + Q6 + Q7 + Q8 + Q9 + Q10
(b) Score 2: Q1 + Q2 + Q3 + Q6 + Q7
(c) Score 3: Q1 + Q2 + Q6
(d) Score 4: Q1 + 2.Q2 + Q6.










Different psychotropic and antiepileptic medication
Lamotrigine (AED/mood stabilizer) 7
Levetiracetam (AED) 3
Risperidone (antipsychotic) 15









Depakote (mood stabiliser) 1
PRN zopiclone (sedative/hypnotic) 1
PRN lorazepam or diazepam (benzodiazepine
sedative/hypnotic/anxiolytic)
18
AED, antiepileptic drug; SSRI, Selective Serotonin Reuptake Inhibitor; SNRI, Serotonin and
norepinephrine reuptake inhibitor; PRN, pro re nata.








result, n (%) P-value
Q1 No 13 (72%) 5 (28%) <0.001
Yes 2 (10%) 19 (90%)
Q2 No 14 (64%) 8 (36%) <0001
Yes 1 (6%) 16 (94%)
Q3 No 10 (63%) 6 (37%) 0.02
Yes 5 (22%) 18 (78%)
Q4 No 4 (50%) 4 (50%) 0.69
Yes 11 (35%) 65 (65%)
Q5 No 6 (55%) 5 (45%) 0.28
Yes 9 (32%) 68 (68%)
Q6 No 8 (73%) 3 (27%) 0.01
Yes 7 (25%) 21 (75%)
Q7 No 8 (57%) 6 (43%) 0.10
Yes 7 (28%) 18 (72%)
Q8 No 10 (56%) 8 (44%) 0.06
Yes 5 (24%) 16 (76%)
Q9 No 8 (53%) 7 (47%) 0.18
Yes 7 (29%) 17 (71%)
Q10 No 5 (57%) 4 (44%) 0.27
(2 categories) Yes 10 (33%) 20 (67%)
Q10 No 5 (57%) 4 (44%) 0.37
(3 categories) Yes, one option 1 (17%) 5 (83%)
Yes, both options 9 (37%) 15 (63%)
DIVA-5-ID, Diagnostic Interview for ADHD in adults with intellectual disability.






1 Q1 2.89 (0.29–29.2) 1.06 0.37
Q2 22.1 (1.24–3947) 3.10 0.04
Q3 2.05 (0.27–15.3) 0.72 0.49
Q6 7.61 (0.57–101) 2.03 0.12
Q7 2.72 (0.32–23.4) 1.00 0.36
2 Q1 5.32 (0.66–43.2) 1.67 0.12
Q2 16.5 (1.05–257) 2.80 0.05
Q6 6.40 (0.54–76.3) 1.86 0.14
DIVA-5-ID, Diagnostic Interview for ADHD in adults with intellectual disability.
a. Odds ratios represent the odds of a positive DIVA-5-ID result for a ‘yes’ response
relative to the odds for a ‘no’ response.
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Stage 4
The diagnostic performance of each of the four scores for the predic-
tion of the DIVA-5-ID result was evaluated (Table 5). The results sug-
gested relatively good diagnostic performance for all four scores, with
all area under the curve values being≥0.86. Score 4 (questions 1, 2 and
6) had the highest area under the curve value (Fig. 1). This score had a
range of values from 0 to 4, a sensitivity of 88%, a specificity of 87%
and a score of ≥2, and was found to be the best predictor of a positive
DIVA-5-ID result. All four scores had a positive predictive value of
>90%, with score 2 being highest at 95% and score 4 being 91%.
The negative predictive values for the four scores were dispersed
(range 65–81%), with score 4 being the highest at 81%. The odds of
a positive test in those with ADHD relative to the odds of a positive
test in those without ADHD was highest in score 2 (70.0), with
score 4 being second highest at 45.5.
Discussion
Diagnosing ADHD in adults with intellectual disability can be chal-
lenging, and there are many barriers to diagnosis (Table 1). Using
the DIVA-5-ID as a diagnostic tool can be resource-intensive for
daily clinical practice, as there is a need to collect comprehensive
past and present history and interview a reliable informant, and it
requires trained specialist clinical input. Thus, screening tools are
of value where ADHD is suspected. However, in a population
with a high prevalence of ADHD, there is no screening tool or deci-
sion-support tool to undertake a full assessment. Equally, as shown
by our study sample, this group has multimorbidity and is subject to
polypharmacy. This innovation in routine clinical practice is the
first evidence-based attempt to develop a screening tool for
ADHD in people with intellectual disability.
This tool has the potential to influence positive change in sup-
porting the health needs of people with intellectual disability. The
obvious benefit is to quickly identify people with intellectual disabil-
ity with suspected ADHD for further diagnostic work-up, i.e. the
DIVA-5-ID. Other benefits include reduction of misdiagnosis
and, by extension, reduction in polypharmacy, particularly in the
prescribing of inappropriate psychotropics in a vulnerable popula-
tion. As shown, the majority of the study sample pre-screening were
on psychotropic medication, with over half (54%) on multiple
drugs. It could be that these drugs were prescribed to manage pre-
senting symptoms of ADHD in the individual, without consider-
ation of an ADHD diagnosis. This could have led to limited
symptom relief. Better screening can lead to improved diagnosis,
improving both health and quality of life for the patient.
Furthermore, it is carer- or patient-led, thus having positive impli-
cations on clinician resource and time.
Implications for patients and their carers/families
Because of cognitive deficits, people with intellectual disability
can be marginalised in their ability to interactively participate in a
Table 5 Performance of different scores for the prediction of DIVA-5-ID result
Score
Range









1 0–9 0.86 (0.75–0.97) ≥6 71% 87% 90% 65% 15.8
2 0–5 0.90 (0.80–0.99) ≥3 83% 93% 95% 78% 70.0
3 0–3 0.90 (0.79–1.00) ≥2 83% 87% 91% 77% 32.5
4 0–4 0.91 (0.81–1.00) ≥2 88% 87% 91% 81% 45.5











0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under receiver operating characteristic curve = 0.9125
Fig. 1 Diagnostic performance of score 4.
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clinical process. Three-quarters of the patients in this study (77%)
had a moderate-to-profound disability, which would affect their
meaningful contribution to the diagnostic or treatment assessments.
This disadvantage can be further compounded by the presence of
ADHD. In these circumstances, clinicians often have to depend
on the narrative from informants. This information from family
members or professional carers could potentially bring an emo-
tional and subjective bias to the diagnostic process. The availability
of a structured questionnaire allows better evidence-based synthesis
to the clinical formulation about the presence or absence of ADHD.
The questionnaire will allow for stepwise discussion with the patient
and other stakeholders and planning, including the justification for
trialling ADHD medication.
Implications for policy and research
ADHD remains an unrecognised comorbidity in people with intel-
lectual disability. This has, in many cases, led to overprescribing of
psychotropic medication, which can lead to several unwanted
effects on well-being, morbidity andmortality.18,19 Further develop-
ment and national adoption of the screening tool could help to miti-
gate these adverse outcomes.
The lack of a screening tool despite the need in this vulnerable
population could also be because of the heterogeneous complex
presentation of this population, particularly with regards to multi-
morbidity, polypharmacy and intellectual disability-specific charac-
teristics confounding the picture. The current questionnaire looks
to overcome these challenges of heterogeneity by using statistical
concepts, and has shown potential for further study. In particular,
multi-site implementation of score 4 (questions 1, 2 and 6; bolded
in the questionnaire) needs to be conducted to see if the clinical
yield is similar to this pilot study. Other psychometric properties
of these three questions may need further research.
Another potential area to explore would be to examine if the
screening questions not only suggest ADHD, but have any discrim-
inating validity in ruling out other reasons for ADHD symptoms,
such as other serious mental illness.
This is a pragmatic single-site study carried out as part of
routine clinical practice. Hence, no advance power calculations on
sampling were made. However, it is worth recognising that the
study was prospective and the clinician investigators were blinded
to the questionnaire results. The identified questions (questions 1,
2 and 6) are predominantly focused on observed behaviour,
which could also be a presentation of other medical and psycho-
logical conditions such as drug-induced akathisia, autism spectrum
disorder, etc. However, it is the study premise that this is not a diag-
nostic tool but a screening tool. It is not suggested to replace the gold
standard of inquiry into such behavioural patterns.
Score 2 (questions 1, 2, 3, 6 and 7) was the other potential alter-
native as it had higher specificity (93%), higher positive predictive
value (95%) and a better odds ratio (70) than score 4. However, as
the focus is on screening, score 4 had a better negative predictive
value and better sensitivity, in addition to only being three questions
(questions 1, 2 and 6). It is worth noting that these three questions
also feature in score 2. In future, larger field trials, it might be worth
considering a more inclusive screening set (i.e. score 2), to revisit
comparisons between score 2 and score 4 as to which would be
better suited.
In the statistical work-up, assumptions had to be made based on
the sample size and expected associations. A P-value of 0.2 was taken
for stage 2 instead of P < 0.05 or P < 0.10, as the data-set was small
and likely to be predisposed to big associations for some questions
that did not reach statistical significance. With a bigger sample, it
is likely significant results would be obtained with similar effect
size. The threshold here was relaxed to allow more variables into
the score. It was felt that to make the scores simpler to calculate in
practice, a simpler strategy of assigning points to each factor
should be used. Using the exact coefficients would mean that more
involved calculations would be required to calculate the score for
each patient, which may limit the use of the scoring system. As out-
lined in the paper, the first scores used equal weighting for each vari-
able. Approximate regression coefficients were used to give different
weightings to the questions for the last of the scores.
It is possible that more people who are engaged or interested in
the support of ADHD responded to the questionnaire than people
who are not. Also, it was not possible to explore the characteristics
of non-responders. This may have introduced bias in the data.
However, the response rate of 50% suggests that this is unlikely.
Also, some questions might be perceived as ambiguous and there
may be some overlap between questions. Carers relying on retro-
spective memory and reports are likely to lead to approximations.
Despite its limitations, the study has captured critical knowledge
and evidence hitherto unavailable in scientific literature.
In conclusion, there is a significant level of underdiagnoses of
ADHD in people with intellectual disability. This has led tomisdiag-
nosis and polypharmacy, particularly for psychotropics. This study
delivers three evidence-based screening questions to assist carers
and clinicians to consider further ADHD diagnostic work-up:
‘Does he/she find hard to sit in one place for long?’, ‘Does he/she
pace up and down most of the time?’ and ‘Is he/she easily distracti-
ble by busy environments?’.
These three questions could be easily incorporated into any pre-
liminary inquiry into a referral for a psychiatric or behavioural
assessment of a person with intellectual disability, to help consider
ADHD and provide better clinical formulation and bespoke treat-
ment of their needs.
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Appendix 1: ADHD screening questionnaire for people with intellectual disability (questions identified for final screening in bold)
Appendix 2: study pathway
 
 
Questionnaire sent to all patients
open to psychiatry team (n = 78)  
Responded (n = 39) Did not respond (n = 39) 
Yes (n = 36)  
One or more questions in the
questionnaire were positive 




DIVA-5-ID administered by first author ensuring relevant history of
childhood from primary and secondary care collected   
No 
Statistical analysis
plan applied  
Question Yes/no (present in the past 6 months)
Tick if this symptom goes back to
childhood
Q1 Does he/she find hard to sit in one place for long?
Q2 Does he/she pace up and down most of the time?
Q3 Does he/she often fidget with their hands/feet?
Q4 Is he/she very impulsive/can’t wait for his turn?
Q5 Does he/she often intrude/interrupt others?
Q6 Is he/she easily distractible by busy
environments?
Q7 Does he/she often move from one task/activity to
another?
Q8 Does he/she appear preoccupied and not listening when
spoken to directly?
Q9 Is he/she forgetful in daily tasks and need frequent
reminders and prompting?
Q10 Does the patient display any challenging behaviour? If yes, please tick the following that apply (you can
choose one or more)
• Physical aggression towards others
• Damage to property
Sawhney et al
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